These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 19459794

  • 1. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD.
    Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
    [Abstract] [Full Text] [Related]

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
    Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, Kalil RN, Pearson TC.
    Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
    [Abstract] [Full Text] [Related]

  • 4. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 5. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F, Rostaing L, Gugenheim J, Durand F, Radenne S, Leroy V, Neau-Cransac M, Calmus Y, Salamé E, Pageaux GP, Duvoux C, Taguieva N, Sinnasse-Raymond G, Sebagh M, Samuel D, Marquet P.
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [Abstract] [Full Text] [Related]

  • 6. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 7. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, Koneru B, Goss J, Preston D, Roberts JP, Spare-the-Nephron Trial Liver Transplantation Study Group.
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [Abstract] [Full Text] [Related]

  • 8. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R.
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [Abstract] [Full Text] [Related]

  • 9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B, Höcker B.
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [Abstract] [Full Text] [Related]

  • 10. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.
    Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 12. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation.
    Ekberg H, van Gelder T, Kaplan B, Bernasconi C.
    Transplantation; 2011 Jul 15; 92(1):82-7. PubMed ID: 21562449
    [Abstract] [Full Text] [Related]

  • 13. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD.
    Transplantation; 2008 Oct 27; 86(8):1043-51. PubMed ID: 18946341
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
    Mourer JS, Hartigh Jd, van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW.
    Transplantation; 2012 May 15; 93(9):887-94. PubMed ID: 22538450
    [Abstract] [Full Text] [Related]

  • 15.  Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key.
    Norero B, Serrano CA, Sanchez-Fueyo A, Duarte I, Torres J, Ocquetau M, Barrera F, Arrese M, Soza A, Benítez C.
    Ann Hepatol; 2012 May 15; 16(1):94-106. PubMed ID: 28051798
    [Abstract] [Full Text] [Related]

  • 16. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan 15; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 17. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S, Janus N, Saliba F, Dumortier J, Duvoux C, Calmus Y, Lorho R, Deray G, Launay-Vacher V, Pageaux GP.
    Liver Transpl; 2009 Sep 15; 15(9):1083-91. PubMed ID: 19718632
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 19. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G, Felldin M, Nordén G, Olausson M, Bäckman L, Gustafsson B, Friman S.
    Transplant Proc; 2010 Dec 27; 42(10):4441-8. PubMed ID: 21168715
    [Abstract] [Full Text] [Related]

  • 20. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients.
    Mourer JS, de Koning EJ, van Zwet EW, Mallat MJ, Rabelink TJ, de Fijter JW.
    Transplantation; 2013 Jul 15; 96(1):49-57. PubMed ID: 23715049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.